Relationship between Proinflammatory and Antioxidant Proteins with the Severity of Cardiovascular Disease in Type 2 Diabetes Mellitus.
Texto completo
Documento similar
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE), Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney
NSAIDs increase the risk of cardiovascular disease in the general population, and although there is little direct evidence for elevated cardiovascular risk with NSAIDs in people
Only a small number of pediatric patients with positive testing for COVID-19 were reported in this global survey: 61 with type 1 diabetes mellitus and 25 with type 2... Their
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart
Pediatric patients with Type 2 Diabetes Mellitus will have a worse fatty acid profile associated with inflammation compared with patients with Metabolic Syndrome
(1) original quantitative studies conducted during the COVID-19 outbreak, (2) patients with chronic disease (diabetes type 1 and type 2, hypertension, hyperlipi- demia, dyslipidemia,
The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled,
In this post-hoc analysis of the ISAACC study, we identified specific inflammatory and cardiovascular disease protein biomarkers associated with severe OSA in patients with a